Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer

Author:

Berger Stephanie1ORCID,Procko Erik23,Margineantu Daciana45,Lee Erinna F678910,Shen Betty W11,Zelter Alex2,Silva Daniel-Adriano212,Chawla Kusum45,Herold Marco J910,Garnier Jean-Marc910,Johnson Richard13,MacCoss Michael J13,Lessene Guillaume91014ORCID,Davis Trisha N2ORCID,Stayton Patrick S1,Stoddard Barry L11,Fairlie W Douglas678910,Hockenbery David M45,Baker David21215ORCID

Affiliation:

1. Department of Bioengineering, University of Washington, Seattle, United States

2. Department of Biochemistry, University of Washington, Seattle, United States

3. Department of Biochemistry, University of Illinois, Urbana, United States

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States

5. Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States

6. Department of Chemistry and Physics, LaTrobe Institute for Molecular Science, Melbourne, Australia

7. Olivia Newton-John Cancer Research Institute, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Australia

8. School of Cancer Medicine, La Trobe University, Melbourne, Australia

9. The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

10. Department of Medical Biology, University of Melbourne, Parkville, Australia

11. Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States

12. Institute for Protein Design, University of Washington, Seattle, United States

13. Department of Genome Sciences, University of Washington, Seattle, United States

14. Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Australia

15. Howard Hughes Medical Institute, University of Washington, Seattle, United States

Abstract

Many cancers overexpress one or more of the six human pro-survival BCL2 family proteins to evade apoptosis. To determine which BCL2 protein or proteins block apoptosis in different cancers, we computationally designed three-helix bundle protein inhibitors specific for each BCL2 pro-survival protein. Following in vitro optimization, each inhibitor binds its target with high picomolar to low nanomolar affinity and at least 300-fold specificity. Expression of the designed inhibitors in human cancer cell lines revealed unique dependencies on BCL2 proteins for survival which could not be inferred from other BCL2 profiling methods. Our results show that designed inhibitors can be generated for each member of a closely-knit protein family to probe the importance of specific protein-protein interactions in complex biological processes.

Funder

National Institutes of Health

Defense Threat Reduction Agency

Howard Hughes Medical Institute

National Science Foundation

Worldwide Cancer Research

Cancer Council Victoria

Pew Charitable Trusts

Consejo Nacional de Ciencia y Tecnología

National Health and Medical Research Council

Australian Research Council

Victorian Government, Australia

Publisher

eLife Sciences Publications, Ltd

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Cited by 70 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3